Importance Of The Field: The renin-angiotensin-aldosterone system (RAAS) is a key regulator of blood pressure (BP), as well as volume and electrolytes, in both hypertensive and normotensive individuals. Inappropriate activation of the RAAS is important in hypertension-induced cardiovascular disease (CVD) and chronic kidney disease (CKD). Renin is the rate-limiting step in the RAAS cascade, which makes direct renin inhibitors (DRIs) an attractive target for RAAS suppression and treatment of hypertension. Current regimens using either angiotensin-converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) result in feedback upregulation of renin and aldosterone breakthrough, which contribute to incomplete suppression of the RAAS. Thereby, aliskiren - alone or in combination - might offer a novel therapeutic intervention to improve suppression of the RAAS, with potential to translate to improved CVD and CKD outcomes.
Areas Covered In This Review: Herein, we present the current state of knowledge of DRIs in the preclinical and clinical realm and their antihypertensive efficacy in relation to cardiovascular and renal risk. Recent clinical trials (2007 - 2009) support the efficacy of aliskiren, and studies suggest the potential for improved CVD and CKD outcomes.
What The Reader Will Gain: An understanding of the mechanism of action of DRIs and a perspective of recent clinical trials.
Take Home Message: The DRI aliskiren is an effective antihypertensive agent that preliminary data suggests has a beneficial effect in CVD and CKD. Combination of aliskiren with an ACEi or ARB may be better tolerated than the ACEi-ARB combination. Future work is needed to further quantify aliskiren's impact on hard CVD and CKD end points.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1517/13543781003781906 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The relationship between the age of onset of hypertension and chronic kidney disease: a cross-sectional study of the American population.
Front Cardiovasc Med
December 2024
Department of Cardiology, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, Fujian, China.
Background: Hypertension can damage multiple target organs. The younger the age of onset of hypertension is, the greater the risk of cardiovascular disease (CVD) and cardiovascular death. Chronic kidney disease (CKD) is a complication of hypertension, but few studies have investigated the relationship between the age of onset of hypertension and CKD.
View Article and Find Full Text PDFInsights into renal damage in hyperuricemia: Focus on renal protection (Review).
Mol Med Rep
March 2025
School of Basic Medicine, Anhui Medical University, Hefei, Anhui 230032, P.R. China.
The incidence of hyperuricemia has increased recently, posing a serious threat to public health. Hyperuricemia is associated with an increased risk of gout, chronic kidney disease (CKD), obesity, metabolic syndrome, type 2 diabetes mellitus, hypertension, hypertriglyceridaemia, metabolic dysfunction‑associated steatotic liver disease, acute kidney injury, coronary heart disease and cardiovascular disease (CVD). These diseases are commonly accompanied by varying degrees of kidney damage.
View Article and Find Full Text PDFKidney transplantation (KT) is the treatment of choice for chronic kidney disease (CKD) patients, but there is a continued loss of grafts in the long-term (50% at 10 years) due to either patient 's death or chronic allograft dysfunction. Metabolic syndrome (MS) is very prevalent after KT (30-40%) and its components contribute to the appearance of non-alcoholic fatty liver disease/metabolic dysfunction-associated fatty liver disease (NAFLD/MAFLD) and non-alcoholic steatohepatitis (NASH), which represents the hepatic component of MS. Furthermore, about 20-40% of KT recipients present early graft inflammation, including subclinical inflammation.
View Article and Find Full Text PDFAssociation between triglyceride-glucose index and cardiovascular disease in US adults with chronic kidney disease: a population-based study.
BMC Cardiovasc Disord
December 2024
Department of Nephrology, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Objectives: Triglyceride-glucose (TyG) index, which is a valuable measure of insulin resistance, has been found to have predictive value for cardiovascular disease (CVD). However, its relationship with CVD among individuals with chronic kidney disease (CKD) has not been thoroughly investigated. This study focused on examining the relationship of the TyG index and CVD among CKD patients in United States.
View Article and Find Full Text PDFThe New Cardiovascular-Kidney-Metabolic (CKM) Syndrome: An Opportunity for CKD Detection and Treatment in Primary Care.
Am J Kidney Dis
December 2024
San Francisco VA Health Care System, San Francisco, CA; University of California, San Francisco, San Francisco, CA; Kidney Health Research Collaborative, San Francisco, CA. Electronic address:
In October of 2023, the American Heart Association (AHA) published a scientific statement and advisory that defined a novel entity, the Cardiovascular-Kidney-Metabolic (CKM) Syndrome. The overall framework proposes that a substantial proportion of cardiovascular disease (CVD) burden is attributable to a syndrome that extends in stages from: Stage 1) obesity, Stage 2) metabolic/kidney risk factors for CVD (diabetes mellitus, chronic kidney disease (CKD), hypertension, and dyslipidemia), Stage 3) subclinical CVD, and finally Stage 4) clinical CVD. The report that describes the CKM paradigm documents the scientific justification for a syndrome, highlights the overlap in risk factors among individuals with obesity, diabetes, CKD, and CVD, and aligns the evidence and guideline statements that address screening, prevention, and management of these conditions.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!